News: HER2

HER2 May Impact Lung Cancer Therapy

Friday, September 21st, 2012

Overcoming therapeutic resistance that inevitably develops is one of the major challenges in treating lung cancer. Non-small cell lung cancers that harbor mutations in the epidermal growth factor receptor (EGFR) are initially responsive to targeted therapies known as EGFR tyrosine kinase inhibitors (TKIs). However, most patients eventually develop resistance to these therapies. One such targeted […]

Arteaga Earns Komen Award

Friday, October 7th, 2011

Carlos L. Arteaga, M.D., professor of Medicine and Cancer Biology and associate director for Clinical Research at Vanderbilt-Ingram Cancer Center (VICC), has been named one of the winners of this year’s Susan G. Komen for the Cure Brinker Awards for Scientific Distinction. The Brinker Awards for Scientific Distinction were established in 1992 to recognize the efforts of […]

Breast Cancer and Personalized Medicine

Wednesday, October 5th, 2011

Dr. Carlos Arteaga, director of the Vanderbilt-Ingram Cancer Center’s breast cancer program, describes how advances in personalized cancer medicine contributes to breast cancer treatment.

Six Subtypes Identified in Breast Cancer

Friday, July 8th, 2011

Vanderbilt-Ingram Cancer Center researchers have identified six subtypes of an aggressive and difficult-to-treat form of breast cancer, called “triple-negative breast cancer (TNBC).” In the July issue of the Journal of Clinical Investigation, Cancer Center Director Jennifer Pietenpol, Ph.D., and colleagues describe the molecular features of these six distinct subtypes and identify chemotherapies to which the […]